Literature DB >> 16988210

Pharmacokinetics of desmopressin administrated as an oral lyophilisate dosage form in children with primary nocturnal enuresis and healthy adults.

Ole Osterberg1, Radojka M Savic, Mats O Karlsson, Ulrika S H Simonsson, Jens Peter Nørgaard, Johan Vande Walle, Henrik Agersø.   

Abstract

The population pharmacokinetics of desmopressin in children with nocturnal enuresis and in healthy adults were compared using a 1-compartment model with first-order absorption and first-order elimination. In addition, the model consisted of a number of transit compartments before absorption to describe a lag-time. The model gave an adequate description of adult as well as children data and provided a statistically significant better fit to data than a standard lag-time model. The main difference in the pharmacokinetics between children and adults was the absorption delay. The pharmacokinetic difference was minor and presumably of no clinical relevance.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16988210     DOI: 10.1177/0091270006291838

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  22 in total

1.  Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies.

Authors:  Radojka M Savic; Daniël M Jonker; Thomas Kerbusch; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-07-26       Impact factor: 2.745

2.  Clinical study shows improved absorption of desmopressin with novel formulation.

Authors:  Nelly Fransén; Susanne Bredenberg; Erik Björk
Journal:  Pharm Res       Date:  2009-03-19       Impact factor: 4.200

3.  Pharmacokinetics of desmopressin administered as tablet and oral lyophilisate formulation in children with monosymptomatic nocturnal enuresis.

Authors:  Pauline De Bruyne; Ann De Guchtenaere; Charlotte Van Herzeele; Ann Raes; Jo Dehoorne; Piet Hoebeke; Erik Van Laecke; Johan Vande Walle
Journal:  Eur J Pediatr       Date:  2013-08-30       Impact factor: 3.183

4.  Evaluation of the nonparametric estimation method in NONMEM VI: application to real data.

Authors:  Paul G Baverel; Radojka M Savic; Justin J Wilkins; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-07-02       Impact factor: 2.745

5.  Semiparametric distributions with estimated shape parameters.

Authors:  Klas J F Petersson; Eva Hanze; Radojka M Savic; Mats O Karlsson
Journal:  Pharm Res       Date:  2009-07-01       Impact factor: 4.200

6.  Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions.

Authors:  Radojka M Savic; Mats O Karlsson
Journal:  AAPS J       Date:  2009-08-01       Impact factor: 4.009

7.  Performance in population models for count data, part I: maximum likelihood approximations.

Authors:  Elodie L Plan; Alan Maloney; Iñaki F Trocóniz; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-08-04       Impact factor: 2.745

8.  Evaluation of an extended grid method for estimation using nonparametric distributions.

Authors:  Radojka M Savic; Mats O Karlsson
Journal:  AAPS J       Date:  2009-09       Impact factor: 4.009

9.  Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption.

Authors:  Justin J Wilkins; Radojka M Savic; Mats O Karlsson; Grant Langdon; Helen McIlleron; Goonaseelan Pillai; Peter J Smith; Ulrika S H Simonsson
Journal:  Antimicrob Agents Chemother       Date:  2008-04-07       Impact factor: 5.191

10.  Is there still a role for desmopressin in children with primary monosymptomatic nocturnal enuresis?: a focus on safety issues.

Authors:  Johan Van de Walle; Charlotte Van Herzeele; Ann Raes
Journal:  Drug Saf       Date:  2010-04-01       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.